Revance Therapeutics, Inc.

Read more
Mark Foley's photo - President & CEO of Revance Therapeutics, Inc.

President & CEO

Mark Foley

CEO Approval Rating

85/100

Founded:

1999

Status:

PublicIndependent CompanyNASDAQRVNC

Annual Revenue
$28.6M
Employees
170
Sector

- -

REVANCE THERAPEUTICS, INC. TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Mark Foley

President & CEO

- -
170
$252.5M
$28.6M
View Profile
1

CEO

- -
16,900
$31.1M
$16B
View Profile
2

David Loew

CEO

86/100
5,800
- -
$2.9B
View Profile
3

Philip Burchard

CEO

90/100
3,151
- -
$1.2B
View Profile
4

Howard W. Robin

President & CEO

88/100
618
$850M
$126M
View Profile
5

Fauad Hasan

Co-Founder & CEO

48/100
3
$47.7M
$2M
View Profile
6

Ram Mandalam

President & CEO

90/100
60
$153.9M
$8.5M
View Profile
7

Michael M. Morrissey

President & CEO

90/100
484
$118.3M
$1.3B
View Profile
8

Antony Loebel

President & CEO

82/100
1,620
- -
$600M
View Profile
9

Sean A. McCarthy

Chairman & CEO

91/100
137
$290.6M
$66.7M
View Profile
10

Sanford J. Madigan

President & CEO

89/100
25
- -
$2M
View Profile

Missing a competitor? Contribute!

Revance Therapeutics, Inc. Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$28.6M

Revance Therapeutics, Inc.'s revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 2.3B. Over the last four quarters, Revance Therapeutics, Inc.'s revenue has grown by 4347.8%. Specifically, in Q1 2021's revenue was $13.3M; in Q4 2020, it was $11.1M; in Q3 2020, it was $3.8M; in Q2 2020, Revance Therapeutics, Inc.'s revenue was $ < 1M.

Revance Therapeutics, Inc. Acquisitions

No recent acquisitions found related to Revance Therapeutics, Inc.

Revance Therapeutics, Inc. Funding History

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Feb 2014
$96M

Equity
Oct 2013
$10M
-
Series E
Apr 2013
$33M
Series E
Feb 2013
$5M
-
Unattributed
Jan 2013
$12.4M
-

Revance Therapeutics, Inc. Investments

No recent investments found related to Revance Therapeutics, Inc.

Revance Therapeutics, Inc. News

Revance Therapeutics, Inc. Press Releases

Social Media

Revance Therapeutics, Inc. Headquarters

7555 Gateway Boulevard

Newark, California94560

1-510-742-3400

Driving Directions »

Trending Companies

Revance Therapeutics, Inc. Summary

ABOUT

Overview

Revance is a biotechnology company that researches and develops novel neuromodulators for aesthetic and therapeutic indications. Revance Therapeutics, Inc. was founded in 1999. Revance Therapeutics, Inc.'s headquarters is located in Newark, California...

CEO

Revance Therapeutics, Inc.'s President & CEO, Mark Foley, currently has an approval rating of 85%. Revance Therapeutics, Inc.'s primary competitors are Allergan, Ipsen Pharma & Merz.

Frequently Asked Questions about Revance Therapeutics, Inc.

  1. When was Revance Therapeutics, Inc. founded?

    Revance Therapeutics, Inc. was founded in 1999
  2. Who is Revance Therapeutics, Inc.'s CEO?

    Revance Therapeutics, Inc.'s CEO is Mark Foley
  3. How much revenue does Revance Therapeutics, Inc. generate?

    Revance Therapeutics, Inc. generates $28.6M in revenue
  4. How much funding does Revance Therapeutics, Inc. have?

    Revance Therapeutics, Inc. has historically raised $252.5M in funding
  1. Where is Revance Therapeutics, Inc.'s headquarters?

    Revance Therapeutics, Inc.'s headquarters is in Newark California, USA
  2. How many employees does Revance Therapeutics, Inc. have?

    Revance Therapeutics, Inc. has 170 employees
  3. Who are Revance Therapeutics, Inc.'s competitors?

    Revance Therapeutics, Inc.'s top competitors are Allergan, Ipsen Pharma, Merz